• AGIO
• BLUE
• FULC
• PFE
• VRTX

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's withdrawal of sickle cell treatment Oxbryta due to death risks may accelerate trials for rival drugs and leaves many patients relying on older treatments like hydroxyurea.